|
Virtual Meetings 2022
Meet The Professor: Optimizing the Use of Hormonal Therapy in the Management of Prostate CancerFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Prof Karim Fizazi, MD, PhD Head of Service and Full Professor Institut Gustave Roussy University of Paris Saclay Villejuif, France Stéphane Oudard, MD, PhD Chief, Medical Oncology Hôpital Européen Georges Pompidou Paris, France Matthew R Smith, MD, PhD Claire and John Bertucci Endowed Chair in Genitourinary Cancers Professor of Medicine Harvard Medical School Director, Genitourinary Malignancies Program Massachusetts General Hospital Cancer Center Boston, Massachusetts SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by an educational grant from Bayer HealthCare Pharmaceuticals. Agenda
MODULE 1: Hormonal Treatment for Nonmetastatic Prostate Cancer MODULE 2: Optimal Use of Secondary Hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer MODULE 3: Current and Future Applications of Hormonal Therapy in the Treatment of Metastatic Castration-Resistant Prostate Cancer MODULE 4: Side Effects Associated with Hormonal Therapy for Prostate Cancer
Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Prof Oudard has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Prof Fizazi — Advisory Board (Honoriaria to Me): CureVac, Orion Corporation; Advisory Board or Speaking Engagements (Honoraria Provided to My Institution): Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Sanofi. Dr Smith — Advisory Committee, Consulting Agreements and Contracted Research: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by an educational grant from Bayer HealthCare Pharmaceuticals. |